Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2

The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway

(2020) Liam Baird et al.   MOLECULAR AND CELLULAR BIOLOGY

Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated Non-Small Cell Lung Cancer

(2019) Jessica A. Hellyer et al.   LUNG CANCER

Molecular Mechanism of Cellular Oxidative Stress Sensing by Keap1

(2019) Takafumi Suzuki et al.   Cell Reports

Oncogenic Signaling Pathways in The Cancer Genome Atlas

(2018) Francisco Sanchez-Vega et al.   CELL

Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment

(2018) Sarah A. Best et al.   Cell Metabolism

Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation

(2017) Kouhei Tsuchida et al.   FREE RADICAL BIOLOGY AND MEDICINE

Integrated genomic characterization of oesophageal carcinoma

(2017)   NATURE

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis

(2017) Rodrigo Romero et al.   NATURE MEDICINE

Synthetic lethality and cancer

(2017) Nigel J. O'Neil et al.   NATURE REVIEWS GENETICS

Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

(2017) Elsa Beyer Krall et al.   eLife

Drugging Undruggable Molecular Cancer Targets

(2016) John S. Lazo et al.   Annual Review of Pharmacology and Toxicology

A Homeostatic Shift Facilitates Endoplasmic Reticulum Proteostasis through Transcriptional Integration of Proteostatic Stress Response Pathways

(2016) Liam Baird et al.   MOLECULAR AND CELLULAR BIOLOGY

p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming

(2016) Tetsuya Saito et al.   Nature Communications

Role of KEAP1 / NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance

(2016) Youngtae Jeong et al.   Cancer Discovery

Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma

(2015) Mingxin Zhang et al.   BMC CANCER

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

(2015) Kornelius Schulze et al.   NATURE GENETICS

NRF2 Mutation Confers Malignant Potential and Resistance to Chemoradiation Therapy in Advanced Esophageal Squamous Cancer

(2015) Tatsuhiro Shibata et al.   NEOPLASIA

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Trans-ancestry mutational landscape of hepatocellular carcinoma genomes

(2014) Yasushi Totoki et al.   NATURE GENETICS

A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

(2013) A. J. Wagner et al.   CLINICAL CANCER RESEARCH

Genome engineering using the CRISPR-Cas9 system

(2013) F Ann Ran et al.   Nature Protocols

Modulation of oxidative stress as an anticancer strategy

(2013) Chiara Gorrini et al.   NATURE REVIEWS DRUG DISCOVERY

Integration of the Unfolded Protein and Oxidative Stress Responses through SKN-1/Nrf

(2013) Kira M. Glover-Cutter et al.   PLoS Genetics

Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming

(2012) Yoichiro Mitsuishi et al.   CANCER CELL

Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma

(2012) Daisuke Inoue et al.   CANCER SCIENCE

A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors

(2012) K. Jhaveri et al.   CLINICAL CANCER RESEARCH

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

Comprehensive genomic characterization of squamous cell lung cancers

(2012)   NATURE

Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers

(2011) Komal Jhaveri et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

(2011) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

SCF/ -TrCP Promotes Glycogen Synthase Kinase 3-Dependent Degradation of the Nrf2 Transcription Factor in a Keap1-Independent Manner

(2011) P. Rada et al.   MOLECULAR AND CELLULAR BIOLOGY

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

(2011) Gina M. DeNicola et al.   NATURE

Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism

(2011) D. Ren et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer

(2011) William K. Oh et al.   UROLOGY

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma

(2010) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Nrf2 and Keap1 Abnormalities in Non-Small Cell Lung Carcinoma and Association with Clinicopathologic Features

(2010) L. M. Solis et al.   CLINICAL CANCER RESEARCH

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

(2010) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

(2010) J E Lancet et al.   LEUKEMIA

Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis

(2010) Deepti Malhotra et al.   NUCLEIC ACIDS RESEARCH

Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals

(2010) M. McMahon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2

(2008) X.-J. Wang et al.   CARCINOGENESIS

Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy

(2008) T. Shibata et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA